Literature DB >> 12542504

Modified chop-chemotherapy plus rituximab for diffuse large b-cell lymphoma complicating ataxia-telangiectasia.

Gabriele Rossi, Marco Zecca, Antonietta Marchi, Piero de Stefano, Luigi Sammarchi, Franco Locatelli.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12542504     DOI： 10.1046/j.1365-2141.2003.04041_4.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  4 in total

1.  Lymphoma Secondary to Congenital and Acquired Immunodeficiency Syndromes at a Turkish Pediatric Oncology Center.

Authors:  Hikmet G Tanyildiz; Handan Dincaslan; Gulsan Yavuz; Emel Unal; Aydan Ikinciogulları; Figen Dogu; Nurdan Tacyildiz
Journal:  J Clin Immunol       Date:  2016-08-04       Impact factor: 8.317

2.  Pilot study of modified LMB-based therapy for children with ataxia-telangiectasia and advanced stage high grade mature B-cell malignancies.

Authors:  J T Sandlund; M M Hudson; W Kennedy; M Onciu; M B Kastan
Journal:  Pediatr Blood Cancer       Date:  2013-07-30       Impact factor: 3.167

3.  The natural history of ataxia-telangiectasia (A-T): A systematic review.

Authors:  Emily Petley; Alexander Yule; Shaun Alexander; Shalini Ojha; William P Whitehouse
Journal:  PLoS One       Date:  2022-03-15       Impact factor: 3.752

Review 4.  Consensus Recommendations for the Clinical Management of Hematological Malignancies in Patients with DNA Double Stranded Break Disorders.

Authors:  Agata Pastorczak; Andishe Attarbaschi; Simon Bomken; Arndt Borkhardt; Jutte van der Werff Ten Bosch; Sarah Elitzur; Andrew R Gennery; Eva Hlavackova; Arpád Kerekes; Zdenka Křenová; Wojciech Mlynarski; Tomasz Szczepanski; Tessa Wassenberg; Jan Loeffen
Journal:  Cancers (Basel)       Date:  2022-04-14       Impact factor: 6.575
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.